Last reviewed · How we verify
NCT07416188
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Phase 1, PHASE2 trial testing LMP744 in Recurrent Glioblastoma in 40 participants. Not yet recruiting.
31 December 2030
Quick facts
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS) |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 22 April 2026 |
| Primary completion | 31 December 2030 |
| Estimated completion | 31 December 2032 |
| Sites | 1 location across United States |
Drugs / interventions tested
- LMP744 — full drug profile →
- Conventional Surgery or Biopsy
Conditions studied
- Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype — all drugs for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype →
- Relapsed Cancer — all drugs for Relapsed Cancer →
- Recurrent Tumor — all drugs for Recurrent Tumor →
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Who can join
Adults 18 to 99, any sex, with Recurrent Glioblastoma or Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells. Objective: To test LMP744 in people with glioblastoma. Eligibility: People aged 18 years or older with glioblastoma that returned after treatment. Design: Participants will be screened. They will have a surgery to remove a small sample of tumor tissue (biopsy) from the brain. This will be done under protocol 03-N-0164. They will stay in the clinic for 1 night. They will also have imaging scans and tests of their heart function. Participants will have a central line installed: A flexible tube will be inserted into a vein in the chest. It will be attached to a port under the skin. This port will be used to draw blood and give medicines without having to insert new needles into a vein. LMP744 will be given through the central line for 5 days in a row. Participants will remain in the clinic for this time. Participants will then have a second surgery to remove as much of their tumor as possible. They will remain in the clinic until they recover from the surgery. Then they will recover at home after surgery. Participants will return to the clinic to receive the study drug for 5 days in a row through the central line, once a month for up to 12 months. Blood tests, heart function tests, and periodic imaging scans will be repeated during these visits. Participants will continue to have telehealth visits every 3 months after they stop taking the drug.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07416188
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LMP744
Trials testing the same drug.
- NCT03030417 — Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas · Phase 1 · completed
Other recruiting trials for Recurrent Glioblastoma
Currently open trials in the same condition.
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07209241 — Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM · Phase 1 · recruiting
- NCT06910306 — Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · NA · recruiting
- NCT07193628 — B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma · Phase 1 · recruiting
- NCT07076472 — Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P · EARLY_PHASE1 · recruiting
Other National Institute of Neurological Disorders and Stroke (NINDS) trials
Trials by the same sponsor.
- NCT07137442 — Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniques · recruiting
- NCT02522611 — Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain · Phase 1, PHASE2 · not yet recruiting
- NCT07511049 — Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study · Phase 2 · not yet recruiting
- NCT07388550 — Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) · Phase 1 · not yet recruiting
- NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07416188 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Neurological Disorders and Stroke (NINDS)
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07416188.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing